240 related articles for article (PubMed ID: 27513212)
21. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.
Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T
J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925
[TBL] [Abstract][Full Text] [Related]
22. Structural insights into NS5B protein of novel equine hepaciviruses and pegiviruses complexed with polymerase inhibitors.
de Albuquerque PPLF; Santos LHS; Antunes D; Caffarena ER; Figueiredo AS
Virus Res; 2020 Mar; 278():197867. PubMed ID: 31972246
[TBL] [Abstract][Full Text] [Related]
23. Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV.
Elfiky AA; Ismail A
Life Sci; 2019 Dec; 238():116958. PubMed ID: 31628915
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of HCV RNA-dependent RNA polymerase activity by aqueous extract from Fructus Ligustri Lucidi.
Kong L; Li S; Han X; Xiang Z; Fang X; Li B; Wang W; Zhong H; Gao J; Ye L
Virus Res; 2007 Sep; 128(1-2):9-17. PubMed ID: 17531344
[TBL] [Abstract][Full Text] [Related]
25. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
[TBL] [Abstract][Full Text] [Related]
26. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
[TBL] [Abstract][Full Text] [Related]
27. Current perspective of HCV NS5B inhibitors: a review.
Patil VM; Gupta SP; Samanta S; Masand N
Curr Med Chem; 2011; 18(36):5564-97. PubMed ID: 22172066
[TBL] [Abstract][Full Text] [Related]
28. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.
Küçükgüzel I; Satılmış G; Gurukumar KR; Basu A; Tatar E; Nichols DB; Talele TT; Kaushik-Basu N
Eur J Med Chem; 2013 Nov; 69():931-41. PubMed ID: 24161679
[TBL] [Abstract][Full Text] [Related]
29. Update on different aspects of HCV variability: focus on NS5B polymerase.
Marascio N; Torti C; Liberto M; Focà A
BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S1. PubMed ID: 25234810
[TBL] [Abstract][Full Text] [Related]
30. Novel 4-thiazolidinones as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase.
Çakir G; Küçükgüzel İ; Guhamazumder R; Tatar E; Manvar D; Basu A; Patel BA; Zia J; Talele TT; Kaushik-Basu N
Arch Pharm (Weinheim); 2015 Jan; 348(1):10-22. PubMed ID: 25449674
[TBL] [Abstract][Full Text] [Related]
31. The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors.
Manfroni G; Cannalire R; Barreca ML; Kaushik-Basu N; Leyssen P; Winquist J; Iraci N; Manvar D; Paeshuyse J; Guhamazumder R; Basu A; Sabatini S; Tabarrini O; Danielson UH; Neyts J; Cecchetti V
J Med Chem; 2014 Mar; 57(5):1952-63. PubMed ID: 24131104
[TBL] [Abstract][Full Text] [Related]
32. Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase.
Lee S; Yoon KD; Lee M; Cho Y; Choi G; Jang H; Kim B; Jung DH; Oh JG; Kim GW; Oh JW; Jeong YJ; Kwon HJ; Bae SK; Min DH; Windisch MP; Heo TH; Lee C
Br J Pharmacol; 2016 Jan; 173(1):191-211. PubMed ID: 26445091
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Anti-HCV Activity of Multiple Punica granatum Extracts and Fractions in Virus-infected Human Hepatocytes.
Rehman S; Ashfaq UA; Ijaz B; Jabeen Z; Riazuddin S
Curr Pharm Biotechnol; 2018; 19(15):1221-1231. PubMed ID: 30608038
[TBL] [Abstract][Full Text] [Related]
34. RacGTPase-activating protein 1 interacts with hepatitis C virus polymerase NS5B to regulate viral replication.
Wu MJ; Ke PY; Horng JT
Biochem Biophys Res Commun; 2014 Nov; 454(1):19-24. PubMed ID: 25305482
[TBL] [Abstract][Full Text] [Related]
35. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
[TBL] [Abstract][Full Text] [Related]
36. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase.
Talele TT; Arora P; Kulkarni SS; Patel MR; Singh S; Chudayeu M; Kaushik-Basu N
Bioorg Med Chem; 2010 Jul; 18(13):4630-8. PubMed ID: 20627595
[TBL] [Abstract][Full Text] [Related]
37. Anti-HCV Activity from Semi-purified Methanolic Root Extracts of Valeriana wallichii.
Ganta KK; Mandal A; Debnath S; Hazra B; Chaubey B
Phytother Res; 2017 Mar; 31(3):433-440. PubMed ID: 28078810
[TBL] [Abstract][Full Text] [Related]
38. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.
Yu H; Fang Y; Lu X; Liu Y; Zhang H
Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500
[TBL] [Abstract][Full Text] [Related]
39. Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .
Prescrire Int; 2015 Jan; 24(156):5-10. PubMed ID: 25734194
[TBL] [Abstract][Full Text] [Related]
40. Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development.
Barreca ML; Iraci N; Manfroni G; Cecchetti V
Future Med Chem; 2011 Jun; 3(8):1027-55. PubMed ID: 21707403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
